Jason Trubiano

Was great hosting you @angelahuttner.bsky.social as our Visiting Professor. We learnt a lot! Not to mention everybody wanting to submit their work to @cmicomms.bsky.social and start UTI clinics!!

Feasibility Trial of Prolonged versus Single-Dose Challenge in Penicillin Allergy We aimed to evaluate the feasibility of conducting a multicenter, double-blind, placebo-controlled trial of prolonged (i.e., multidose) compared with single-dose amoxicillin challenge in patients w...

#PROSPECTOR Trial is out in NEJM Evidence 🔥

➡️ evidence.nejm.org/doi/full/10....

✅ 1st double-blind, placebo RCT in #drugallergy
✅ Pilot feasibility RCT
✅ 1-dose vs 5-day amoxicillin challenge in delayed/unknown #penicillinallergy

We’re going to answer… Is 1 dose ever enough? 👀 #PROSPECTOR2

Feasibility Trial of Prolonged versus Single-Dose Challenge in Penicillin Allergy We aimed to evaluate the feasibility of conducting a multicenter, double-blind, placebo-controlled trial of prolonged (i.e., multidose) compared with single-dose amoxicillin challenge in patients w...

#PROSPECTOR Trial is out in NEJM Evidence 🔥

➡️ evidence.nejm.org/doi/full/10....

✅ 1st double-blind, placebo RCT in #drugallergy
✅ Pilot feasibility RCT
✅ 1-dose vs 5-day amoxicillin challenge in delayed/unknown #penicillinallergy

We’re going to answer… Is 1 dose ever enough? 👀 #PROSPECTOR2

💊Drug Hypesensitivity Symposium 2026 - #DHS2026
Registrations are now open for our amazing 3-day #drugallergy & #antibioticallergy program in Melbourne 23-25th October 2026.

Stellar international🌏speaker lineup. @allergy-eaaci.bsky.social @thedohertyinst.bsky.social

➡️https://dhs2026.org/

💊Drug Hypesensitivity Symposium 2026 - #DHS2026
Registrations are now open for our amazing 3-day #drugallergy & #antibioticallergy program in Melbourne 23-25th October 2026.

Stellar international🌏speaker lineup. @allergy-eaaci.bsky.social @thedohertyinst.bsky.social

➡️https://dhs2026.org/

The largest adult #penicillinallergy study ever undertaken - The iNAAN study @thedohertyinst.bsky.social @unimelb.bsky.social - 52 hospitals, 8 countries and over 5000 patients….Real world proof of the safety and effectiveness of inpatient DOC! Stay tuned #AMS folks 👀Results soon!

Is one dose ever enough? The PROSPECTOR 🪓 Trial will answer - A international double blind placebo controlled trial of 1 dose vs 5 day for #penicillinallergy. This week we recruited our 100th patient! 🎉 @thedohertyinst.bsky.social

In high-income countries, up to 11.5% of adults report a penicillin allergy, and in high-risk groups prevalence can reach 35%. However, more than 90% of these labels are inaccurate, resulting in substantial clinical and public health consequences in hospitals and communities #idsky

🆕🔥State-of-the-Art Review with 🌟s @trubianojason.bsky.social : Antibiotic Allergy—A Multidisciplinary Approach to Delabeling #idsky
url: academic.oup.com/cid/article/...

Congratulations Elise Mitri from NACE, Austin Health & The Peter Doherty Institute presenting the iNAAN Trial results - > 5000 pts & 1500 inpatient #penicillinallergy DOC performed. Safe irrespective of stakeholder with significant prescribing gains. Largest inpatient penicillin allergy study 👏🎉

Is one dose enough?! Great talk from Dr Rose for the #PROSPECTOR #penicillinallergy #RCT at #EAACI HK Summer School. 6.7% increase in immune mediated reactions with prolonged oral challenge. Looking forward to #PROSPECTOR2 definitive phase III study to change practice!

Excited to be at EAACI Hong Kong School 2025 Hosted by Prof Li. Can’t wait for Elise Mitri from The Peter Doherty Institute to present the #iNAAN Results - #PenicillinAllergy #delabing Global Implementation! Dr Rose will present #PROSPECTOR1 - is one dose enough to delabel penicillin allergy?!? ‼️👀

Thank you @eurekaprizes.bsky.social for the opportunity and my research team Austin Health & Doherty Institute for driving the research in #antibioticallergy #EurekaPrizes

Can’t say no to that!

Another validation of SULF-FAST form Canadian data about to drop! 🎤

#ESCMIDGlobal #FOMO…. Watching online the amazing @elisemitri.bsky.social and thanks to @cmicomms.bsky.social for publishing this work! Not missing another #ESCMIDGlobal!!

Hopefully can get a # going for the conference - #ASID2025 ? Get some of the proffered papers and new research out from #EMCR #IDResearch #Infectiousdiseases

asidaud.bsky.social

Follow our 🇦🇺🇳🇿 ID Society #ASID asidaud.bsky.social 🏆 Great to see you on #bsky 👏

ASID Annual Scientific Meeting kicked off yesterday in Canberra. The pre-conference workshop hosted by Therapeutic Guidelines Australia attracted over 120 attendees and was a very engaging and informative session. The formal program commences tomorrow in what will be one of the largest ASM’s.

Perioperative Penicillin and Cephalosporin Antibiotic Allergy Assessment and Testing This pilot randomized clinical trial assesses the feasibility and safety of using a smartphone application for antibiotic allergy assessment and delabeling in anesthesiologist-led clinics among patien...

Well done team 👏 Perioperative Penicillin and Cephalosporin Antibiotic Allergy Assessment and Testing: The PREPARE Randomized Clinical Trial jamanetwork.com/journals/jam...

We randomised our first patients yesterday into the #PROSPECTOR2 ⛏️ study - international superioty trail of 1 dose versus day challenge for #penicillinallergy. “Is one dose ever enough….”

Best thing about #AAAAI25 is the start of the #JPCoffeeTour! #SanDiego #DrugAllergyChat

The Global Prevalence of Reported Penicillin Allergy: A Systematic Review and Meta-Analysis Patients labelled with penicillin allergy (PenA) often receive broader spectrum antibiotics, associated with antimicrobial resistance and poorer outco…

www.sciencedirect.com/science/arti... - nice review and global prevalence number!

Influenza Vaccination Strategies in Patients with Hematologic Cancer | NEJM In this trial involving patients with hematologic cancers, the immune responses that were elicited were similar for adjuvanted-dose and standard-dose influenza vaccines.

Very proud of this hard work & team effort from all involved! Limited benefit of adjuvanted flu 💉 & 2 vs 1 dose in pts w/ MM, CLL or NHL. @ncicancer.bsky.social @petermaccc.bsky.social @benwteh.bsky.social @trubianojason.bsky.social @michyong.bsky.social @nejm.org www.nejm.org/doi/full/10....

The long-term sustainability of a pharmacist-led antimicrobial stewardship penicillin allergy delabelling ward round: A prospective cohort study. Inpatient penicillin allergy is associated with inappropriate antibiotic prescribing and adverse patient outcomes. We reviewed the long-term effectiveness, safety and antimicrobial stewardship impacts of a pharmacist-led penicillin allergy delabelling ward round.

📣 @elisemitri.bsky.social et al prospectively assessed 477 inpatients with #penicillin allergy. 166 were low-risk & underwent oral challenge: 158 (95%) delabeled. 111 (type A allergy) delabeled without challenge.
➡️ No SAE
#IDSky #MedSky
@trubianojason.bsky.social
www.cmi-comms.com/article/S295...

The long-term sustainability of a pharmacist-led antimicrobial stewardship penicillin allergy delabelling ward round: A prospective cohort study. Inpatient penicillin allergy is associated with inappropriate antibiotic prescribing and adverse patient outcomes. We reviewed the long-term effective…

🆕💫Prospective cohort study
The long-term sustainability of a pharmacist-led antimicrobial stewardship penicillin allergy delabelling ward round with 🌟 @trubianojason.bsky.social @cmicomms.bsky.social #idsky
www.sciencedirect.com/science/arti...

Loved this ❤️ Talk of the #drugallergy town!

1000 direct oral #penicillinallergy challenges in the prospective iNAAN study 🎉- 39 hospitals and 7 countries 😳. The largest adult penicillin challenge study! Well done @elisemitri.bsky.social 👏👏 and all collaborators! @escmid.bsky.social data coming hopefully to #ESCMIDglobal 2025!

Altered IL-6 signalling and risk of tuberculosis: a multi-ancestry mendelian randomisation study Our findings propose a causal relationship between reduced IL-6 signalling and lower risk of tuberculosis, akin to the effect seen in other IL-6 mediated diseases. This study suggests that IL-6 antago...

🚨 Delighted to share our paper defining a new role for IL-6 in TB. 🚨

We used genetic variation to show *reduced* IL-6 signalling is causally associated with *lower* risk of TB.

Lead author @gushamilton.bsky.social

#TBSky #IDSky #ImmunoSky www.thelancet.com/journals/lan...
Thread 👇 (1/8)

The incredibly impressive Ouli Xie is presenting his PhD completion seminar on Monday Nov 25 at 12.30pm AEDT.

"The clinical, epidemiological, and evolutionary intersection between Streptococcus dysgalactiae subspecies equisimilis and Streptococcus pyogenes"

unimelb.zoom.us/j/8944229688...?